Roundup: Fred Launches Third-Party App Marketplace and More Information

Fred launches third-party app marketplace for pharmacies

Australian pharmacy IT solutions provider Fred IT Group has launched an online marketplace for third-party apps for pharmacies.

Called Fred Marketplace, the web-based hub offers solutions that have been approved and tested for use with Fred’s software, including apps and integrations for bots, e-commerce, business intelligence, services clinics, medication information and medication management, loyalty and payment.

Third-party solutions come from Fred’s trusted vendor partners, BD, Dataology, GuildLink, LifeSmart, MIMs, Modeus, Storbie, StrongRoom, Tyro and Willach Pharmacy Solutions.

The market will continue to attract new software partners and approved applications as it expands.


University of South Australia researchers develop fiber sensors to remotely monitor patients

Scientists at the University of South Australia have developed tiny fiber optic sensors to remotely track the position of patients with painful pressure sores in their beds.

“Each year, thousands of elderly Australians in hospitals and nursing homes suffer from pressure sores, or ulcers, which take a long time to heal and can be fatal. At the very least, these injuries can cause severe pain , disrupt sleep, affect their mood, as well as their rehabilitation, mobility and quality of life,” said Dr. Stephen Warren-Smith, the principal investigator behind the new technology.

Fiber sensors are attached to the top surface of a mattress to monitor movement and record heart and breathing rates.

By sensing their breath, the discrete sensors can detect when a patient rolls over, leaves a bed or remains still. Nurses can be notified if a patient has not moved for hours so they can adjust their position.

Current methods of monitoring patients with pressure ulcers use weight-based sensors, which cannot predict when a patient leaves the bed until their feet touch the floor. Camera-based technologies are also used, although privacy is a major concern.


EpiAxis Therapeutics, partner of Peptilogics for AI drug discovery

Australian drug developer EpiAxis Therapeutics and US-based biotech company Peptilogics will harness AI in drug discovery to inhibit epigenetic oncology targets.

Their project will use Peptilogics’ Nautilus AI platform, as well as EpiAxis’ expertise in epigenetics, to advance drug discovery for cancers that elude existing therapies through epigenetic change, including metastatic breast cancer.

“We will focus on lead optimization using Peptilogics’ Nautilus platform, which combines proprietary deep generative models, predictive models, and biophysical simulation to design optimized multiparameter peptides with [the] potential to address novel and historically challenging drug targets,” said Nicholas Nystrom, CTO of Peptilogics.

This partnership follows EpiAxis’ recently concluded clinical trial which, for the first time, used an epigenetic inhibitor alongside chemotherapy to treat metastatic cancer.

Comments are closed.